EMERGENT BIOSOLUTIONS INC. Advertising Expense
EMERGENT BIOSOLUTIONS INC. (EBS) reported Advertising Expense of $6.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. advertising expense for fiscal 2025 was $6.60M, a 71.30% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. advertising expense for fiscal 2024 was $23.00M, a 14.50% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. advertising expense for fiscal 2023 was $26.90M, a 212.79% increase from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. advertising expense for fiscal 2022 was $8.60M.
| Period end | Advertising Expense 12 month |
|---|---|
| 2025-12-31 | $6.60M 10-K · filed 2026-02-27 |
| 2024-12-31 | $23.00M 10-K · filed 2026-02-27 |
| 2023-12-31 | $26.90M 10-K · filed 2026-02-27 |
| 2022-12-31 | $8.60M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |